---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-115418"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:05:47.374089+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cara Q3 net loss $23.2M; KORSUVA revenue $16.2M, 180K vials shipped

## Summary
- Net loss $23.2M ($0.43/share) vs $1.0M loss ($0.02) in Q3 2021; total revenue $10.8M down from $20.3M.
- KORSUVA injection net sales $16.2M incl. $7.4M profit-share from Vifor; ~180K vials shipped to dialysis centers.
- Discontinued Phase 2 PBC trial due to slow enrollment; FDA meeting in 4Q22 to discuss NP pivotal program.
- Cash $179.5M at Sept 30, 2022 (Dec 2021: $236.8M); expects to fund ops into first half 2024.
- Appointed Ryan Maynard as CFO and Lisa von Moltke to Board of Directors.

## SEC filing metadata
- accession: 0001104659-22-115418
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465922115418/0001104659-22-115418-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465922115418/tm2229821d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-115418
- JSON: https://secwatch.observer/filing/0001104659-22-115418.json
- Plain text: https://secwatch.observer/filing/0001104659-22-115418.txt

## Key facts
- Earnings Releases
  Tvardi Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $16.2M.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $16.2M
  - Result: reported results
  source text: Cara Therapeutics Reports Third Quarter 2022 Financial Results – Net revenue was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA® (difelikefalin) injection
  evidence_url: https://www.sec.gov/Archives/edgar/data/1346830/000110465922115418/0001104659-22-115418-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.